Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Thoracic Disease|March 30, 2018
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancerSandrine Niyongere, Andreas Saltos, Jhanelle E Gray
Leukemia & Lymphoma|April 12, 2023
Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemiaMoaath K Mustafa Ali, Matthew T Williams, Elizabeth M Corley, et al.
BMC Medical Genetics|December 22, 2004
Allele frequencies of hemojuvelin gene (HJV) I222N and G320V missense mutations in white and African American subjects from the general Alabama populationJames C Barton, Charles A Rivers, Sandrine Niyongere, et al.
Pharmaceuticals (Basel, Switzerland)|June 21, 2020
Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaSandrine Niyongere, Gabriela Sanchez-Petitto, Jack Masur, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 11, 2023
Olanzapine within steroid-sparing antiemetic regimen to prevent chemotherapy-induced nausea and vomiting in patients with acute leukemia receiving multi-day intensive chemotherapyGrace Hsu, Ciera Bernhardi, Justin Lawson, et al.
Leukemia Research Reports|November 10, 2022
Therapy-related B-lymphoblastic leukemia after multiple myelomaMichael E Kallen, Rima Koka, Zeba N Singh, et al.
Cancer Research Communications|January 29, 2024
Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal DegradationJonelle K Lee, Aditi Chatterjee, Mario Scarpa, et al.
Molecular Cancer Therapeutics|February 11, 2021
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal DegradationMario Scarpa, Prerna Singh, Christopher M Bailey, et al.
Cancer Chemotherapy and Pharmacology|March 7, 2021
Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimensSarah M Kashanian, Noa G Holtzman, Ciera L Patzke, et al.
Frontiers in Oncology|April 18, 2022
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort StudyMoaath K Mustafa Ali, Elizabeth M Corley, Hanan Alharthy, et al.
Pageof 3